Skip to content

Pediatrics Community

  • The Pediatrics Community
  • Knowledge
  • Calendar
  • The Directory
  • ADD a LISTING!
13 Jan 2014DataPharmacology

Omalizumab

Omalizumab for asthma (meta-analysis). Four studies tracked the change in FEV1 predicted in adults and children with moderate to severe asthma, receiving subcutaneous omalizumab + steroid vs placebo + steroid. Mean difference > 0 favors omalizumab. DATASOURCE: Cochrane Database of Systematic Reviews. WIDGET: factgraphs.org

asthmameta-analysismonoclonal antibodiesomalizumab

Post navigation

Previous Post
Next Post
Copyright © 2026 Company Inc. • Address • Tel: 42-898-4363
Proudly powered by WordPress and Listable by Pixelgrade.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Pediatrics Community
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.